BIIB017

DRUG2 trials

Sponsors

Johns Hopkins University, Biogen

Conditions

Relapsing Multiple SclerosisRelapsing Remitting Multiple Sclerosis

Phase 3

Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis

WithdrawnNCT01337427

Johns Hopkins UniversityRelapsing Remitting Multiple Sclerosis

Start: 2010-08-31End: 2013-08-31Updated: 2014-09-15

Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)

CompletedNCT01939002

BiogenRelapsing Multiple Sclerosis

Start: 2013-11-30End: 2015-11-30Updated: 2017-01-25

Related Papers

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis

Therapeutic Advances in Neurological Disorders2018-01-019 citations